- Meeting abstract
Intestinal ischemia and reperfusion: beneficial effects of a platelet activating factor antagonist
Critical Care volume 3, Article number: P085 (2000)
Gut barrier dysfunction in conditions associated with intestinal ischemia and reperfusion (I/R) might contribute to the further development of multiple organ dysfunction. The present study evaluates the effects of platelet activating factor (PAF) antagonist in intestinal I/R injury.
Intestinal ischemia was induced by clamping of the superior mesenteric artery for 40 min followed by 12 h reperfusion. 15 min after the end of ischemia, the rats received intraperitoneal injections of saline or the PAF antagonist lexipafant (5 mg/kg), repeated after 6 h in the groups subjected to 12 h reperfusion. Myeloperoxidase (MPO) content in the small intestine, serum levels of interleukines-1 and 6, plasma protease inhibitors and intestinal endothelial and epithelial permeability were assesed.
Intestinal I/R resulted in intestinal barrier dysfunction with pronounced plasma leakage to the intestinal lumen. A protely plasma activity was evident. MPO content significantly increased as did levels of interleukines. Treatment with the PAF inhibitor partly, though not fully, restored the changes caused by I/R.
PAF seems involved in the release of cytokines and consumption of protease inhibitors following intestinal I/R and the associated impairment of intestinal barrier integrity. Treatment with a PAF antagonist was effective in restoring changes caused by I/R, though not reaching normal levels.
About this article
Cite this article
Andersson, R., Sun, Z., Wang, X. et al. Intestinal ischemia and reperfusion: beneficial effects of a platelet activating factor antagonist. Crit Care 3 (Suppl 1), P085 (2000). https://doi.org/10.1186/cc459
- Superior Mesenteric Artery
- Platelet Activate Factor
- Intestinal Barrier
- Intestinal Ischemia
- Barrier Dysfunction